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Abstract: Polymeric nanoparticles that combine dexamethasone and naproxen reduce inflammation
and synergistically inhibit Interleukin-12b (Il12b) transcription in macrophages. This effect can be
the result of a cyclooxygenase-dependent or a cyclooxygenase-independent mechanism. The aim
of this work is to obtain potent anti-inflammatory polymeric nanoparticles by the combination
of dexamethasone and ketoprofen, one of the most efficient cyclooxygenase-inhibitors among
non-steroidal anti-inflammatory drugs, with appropriate hydrodynamic properties to facilitate
accumulation and co-release of drugs in inflamed tissue. Nanoparticles are spherical with
hydrodynamic diameter (117 ± 1 nm), polydispersity (0.139 ± 0.004), and surface charge (+30 ± 1 mV),
which confer them with high stability and facilitate both macrophage uptake and internalization
pathways to favor their retention at the inflamed areas and lysosomal degradation and drug release,
respectively. In vitro biological studies concluded that the dexamethasone-loaded ketoprofen-bearing
system is non-cytotoxic and efficiently reduces lipopolysaccharide-induced nitric oxide release. The
RT-qPCR analysis shows that the ketoprofen nanoparticles were able to reduce to almost basal levels the
expression of tested pro-inflammatory markers and increase the gene expression of anti-inflammatory
cytokines under inflammatory conditions. However, the synergistic inhibition of Il12b observed in
nanoparticles that combine dexamethasone and naproxen was not observed in nanoparticles that
combine dexamethasone and ketoprofen, suggesting that the synergistic trans-repression of Il12b
observed in the first case was not mediated by cyclooxygenase-dependent pathways.
Keywords: nanoparticles; ketoprofen; dexamethasone; inflammation; macrophages; M1 and M2
markers; Il12-p40 subunit
1. Introduction
Interleukin-12 (IL12) and interleukin-23 (IL23) have recently emerged as therapeutic targets in
the treatment of autoimmune/inflammatory diseases and chronic inflammatory diseases in which
the T cell dominates as the primary dysfunctional cells [1–3]. IL12 and IL23 are mainly produced by
antigen-presenting cells like macrophages and dendritic cells, and they play a key role in naïve T-cells
differentiation to Th1 and Th17 cells, respectively [4]. Their combined inhibition has demonstrated
potential in the treatment of a wide range of autoimmune/inflammatory diseases [5–8]. In 2000, it was
discovered that IL12 and IL23 share the IL12-p40 subunit [9], and since then, its inhibition has become
of therapeutic relevance. In fact, the FDA has recently approved Sterala (ustekinumab), a monoclonal
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antibody against this IL12-p40 subunit, for the treatment of Crohn’s disease, psoriasis, psoriatic arthritis,
and plaque psoriasis [8,10]. In a previous work, our group demonstrated that the nanoparticles (NPs)
combining naproxen (NAP) and dexamethasone (Dx) have a synergistic effect on the repression of Il12b
transcript levels, the gene that codifies for IL12-p40 in macrophages [11]. However, the mechanism
for this synergistic inhibition was not elucidated. Currently, it is widely accepted that beneficial
effects of non-steroidal anti-inflammatory drugs (NSAIDs) are mainly mediated by cyclooxygenase
(COX)-dependent mechanisms but also via COX-independent pathways [12]. In fact, NSAIDs are
known to exert anti-inflammatory effects through COX inhibition, ERK, JNK and p38 MAPK pathways,
and 5-lipoxygenase (5-LO) pathways, among others [13]. There are reports of modulation of Il12b
expression in antigen-presenting cells (i.e., macrophages and dendritic cells, mainly) through all
the aforementioned pathways [13–17]. NSAIDs as potent COX inhibitors, reduce the metabolism of
arachidonic acid (AA) through the COX-dependent pathway reducing production of prostaglandins.
However, accumulation of AA leads to increased metabolism through the 5-LO alternative pathway [18].
On the other hand, Dx inhibits phospholipase A2 (PLA2), the enzyme that mediates the production of
AA from membrane phospholipids, reducing AA accumulation and both COX and 5-LO metabolic
pathways [19]. Furthermore, regarding COX-independent mechanisms, Dx has been demonstrated to
inhibit Il-12p40 expression in LPS-stimulated human monocytic cells by down-regulating the activation
of JNK MAPK pathway [20]. According to that, NSAIDs/Dx synergistic suppression of Il12b expression
could be the result of a COX-dependent or COX-independent mechanism. This work aims to prepare
a new family of nanoparticle systems that combine physically entrapped Dx and covalently linked
ketoprofen (KT), a well-known NSAID presenting several orders of magnitude lower IC50(COX) than
NAP [21,22], in order to obtain a system with a potent anti-inflammatory capacity and to elucidate if
the COX-dependent mechanism plays a key role in the synergistic Il12b repression observed for the
Dx/NAP system [11]. For this purpose, a methacrylic derivative of KT was prepared and copolymerized
with 1-vinylimidazole (VI) by free radical polymerization obtaining a pseudo-gradient microstructure
that enables self-assembly into NPs in aqueous media. The stability of the system and most suitable
storage conditions were evaluated as a function of concentration, pH, final volume, and freeze-drying.
Hydrodynamic properties and surface charge of the NPs were optimized in order to favor macrophage
uptake and the endocytic pathways for lysosomal targeting. Macrophage rapid uptake will favor the
enhanced leaky vasculature and inflammatory cells sequestration (ELVIS) effect [11], and lysosome
was considered the most appropriate organelle to favor enzymatic degradation and pH-mediated
co-delivery of the two drugs incorporated in the NPs [23]. Dx encapsulation efficiency was also
evaluated by HPLC. Finally, biological activity of the system was studied by determining cytotoxicity,
changes in the expression of LPS-induced inflammatory marker genes (i.e., Il12b, Il23a, and Tnfa), and
anti-inflammatory marker genes (i.e., Vegfa, Tgfb1, and Il10) in RAW264.7 macrophages.
2. Materials and Methods
2.1. Synthesis and Characterization of Ketoprofen-Derived Monomer (HKT)
The methacrylic derivative of ketoprofen (HKT) (Figure 1a) was synthesized via esterification
reaction as previously described for its homologous based on ibuprofen and naproxen [24,25]. Briefly,
KT (TCI, 1 equiv) was dissolved in dichloromethane (DCM, Aldrich, St. Louis, MO, USA). Then, purified
2-hydroxyethyl methacrylate (HEMA, Aldrich, 1 equiv) and 4-dimethylaminopyridine (DMAP, Aldrich,
0.1 equiv) were added, and dicyclohexylcarbodiimide (DCC, 1 equiv. Fluka, Buchs, Switzerland) was
slowly dropped into the reaction mixture under magnetic stirring and inert atmosphere (N2 (g)). The
reaction took place overnight, under continuous stirring, and at room temperature. The resultant
mixture was filtered to eliminate N,N′-diciclohexylurea (DCU) salt, and, subsequently, washed with
water and a sodium bicarbonate-saturated solution (NaHCO3, Panreac, Barcelona, Spain). Saturated
NaCl (Panreac) and anhydrous magnesium sulphate (MgSO4, Qemical, Esparraguera, Spain) were
used to dry the final solution before DCM evaporation under reduced pressure. The structure and
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purity of the product were determined by proton nuclear magnetic resonance (1H-NMR) in a Varian
Mercury 400 MHz equipment using deuterated chloroform (CDCl3, Aldrich) as a solvent at 25 ◦C.Pharmaceutics 2 20, 12, x FOR PEER REVIEW 7 of 19 
 
 
Figure 1. (a) Synthesis and 1H-NMR spectra of the methacrylic derivative of ketoprofen (HKT), and 
(b) synthesis via free radical copolymerization and 1H-NMR spectra of poly(HKT-co-VI) copolymer. 
Note: n * and o * refer to the cis and trans protons of the carbonyl group. 
The copolymers molar composition was quantitatively determined from their corresponding 1H-
NMR spectra by considering the signals between 0.1 and 2.8 ppm assigned to eight protons of HKT 
(CH3-k, CH3-o, and CH2-n) and two protons of VI (CH2-1) and the signals between 6.5 and 8.0 ppm 
resultant from nine aromatic protons of HKT (CH-a-i) and three aromatic protons of VI (CH-3,4,5). The 
differences among copolymer HKT molar content (FHKT) and feed HKT molar content (fHKT) are 
explained by the two orders of magnitude difference in the reactivity ratios of the monomers (Figure 
S1) and the fact that total conversion was not reached. The molecular weight (Mw) of the copolymer 
was 99 KDa, with polydispersity index values of 2.3 that correspond to those obtained from a 
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temperature (Tg = 54 °C) indicating that no-phase segregation was observed, although a pseudo-
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presented a hydrophobic core mainly formed by covalently linked KT and a hydrophilic shell mainly 
formed by VI. Nanoprecipitation method was performed as previously described, and NPs were 
labeled as KT NPs. SEM micrograph of the NPs confirmed the successful NPs’ formation presenting 
spherical shape, slight polydispersity in size, and diameter of about 100 nm (Figure S2). Regarding 
hydrodynamic properties, a positive ξ value of +30 ± 1 mV was obtained, confirming the presence of 
VI protonable amine groups on the surface of the NPs and, according to literature, an indication of 
Figure 1. (a) Synthesis and 1H-NMR spectra of the ethacrylic derivative of ketoprofen ( KT), and
(b) synthesis via free radical copoly erization and 1H-NMR spectra of poly(HKT-co-VI) copolymer.
ote: n * and o * refer to the cis and trans protons of the carbonyl gro .
HKT: 1H NMR (400 MHz, CDCl3) δH 7.76–7.31 (m, 9H), 5.96–5.91 (s, 1H), 5.45 (s, 1H), 4.35–4.17 (m, 4 ),
3.76 (q, J = 7.2 Hz, 1H), 1.80 (s, 3H), 1.47 (d, 3H).
2.2. Synthesis and Characterization of Copolymer of Ketoprofen-Based Methacrylic Monomer and 1-vinyl
imidazole, poly(HKT-co-VI)
The copolymer based on HKT and 1-v nylimidazole (VI, Aldrich) was prepared via f ee radical
polymerization (Figure 1b) and a feed molar content in HKT (FHKT) of 0.4, and an initial mono ers
concentration ([M]) of 0.5 M were use . In summary, HKT and VI were dissolved in dimethylsulfoxide
(DMSO, Scha lau, Barcelona, Spain) at concentrati n of 0.5 M, and after 10 min of deoxygenation
with N2 (g), 2,2′-azobisisobutyronitrile (AIBN, 1.5 × 10−2 M, Merck, Kenilworth, NJ, USA) was ad ed.
After 12 h at 60 ◦C, the copolymer zation resultant mixture was dialyzed (Spectrum Laboratories,
3.5K molecular weight cut-off) against distilled water for 72 h, and the copolymer was isolated by
freeze-drying as a w ite powder. Reactivity ratios of HKT and VI were studied by in situ 1H-NMR
monitorization (see Supplementary Information for further details).
poly(HKT-co-VI)(48:52) (HKT48): 1H NMR (400 MHz, DMSO-d6) δH 7.95–6.45 (m, 12H (3VI + 9HKT)),
4.53–3.39 (m, 5H (5HKT)), 3.22–2.73 (s, 1H (1VI)), 2.28–0.10 (m, 10H (2VI + 8HKT))
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2.2.1. Proton Nuclear Magnetic Resonance (1H-NMR)
1H-NMR was performed in a Varian Mercury equipment operating at 400 MHz. Spectra were
recorded by dissolving samples in deuteraded DMSO (DMSO-d6) at 25 ◦C. Copolymer composition
was calculated using MestreNova 9.0 from the 1H-NMR integral between 7.92–6.47 ppm corresponding
to the aromatic protons of both monomers and the integral between 2.28–0 ppm, which corresponds to
protons of the methyl groups k and o of HKT and protons 1 and n from the main hydrophobic carbon
chain of VI and HKT, respectively (Figure 1b).
2.2.2. Size Exclusion Chromatography (SEC)
HKT-based copolymer apparent average molecular weight (Mn and Mw) and polydispersity index
(Ð) were determined by SEC, using a Perkin-Elmer Isocratic LC pump 250 coupled to a refraction
index detector (Series 200). Two Resipore columns (250 mm × 4.6 mm, Varian, Palo Alto, CA, USA)
were used as solid phase, degassed chromatographic-grade dimethylformamide (DMF, 0.7 mL/min,
Scharlau, Barcelona, Spain) with LiBr (0.1% w/v) was used as eluent, and temperature was fixed
at 70 ◦C. Monodisperse PMMA standards (Scharlau) with molecular weights between 10,300 and
1,400,000 Da were used to obtain the calibration curve. Data were analyzed using the Perkin-Elmer LC
solution program.
2.2.3. Differential Scanning Calorimetry (DSC)
Glass transition temperature (Tg) was determined by differential Scanning Calorimetry (DSC) with
a Perkin Elmer DSC8500 interfaced to a Pyris thermal analysis data system. Dried samples (3–5 mg)
were placed in aluminium pans and heated from −20 to 120 ◦C at a constant speed of 20 ◦C/min. Tg
was taken as the midpoint of the heat capacity transition.
2.3. Preparation and Characterization of Self-Assembled Nanoparticles
2.3.1. Nanoprecipitation Method
Poly(HKT-co-VI)-based NPs were prepared via nanoprecipitation method. Concisely, an organic
solution (acetone (Scharlau): ethanol (Scharlau), 80:20 (v/v)); of the copolymer (10 mg/mL) was added
dropwise to an aqueous buffer solution at pH 4 (0.1 M acetic acid and 0.1 M NaCl), a pH below the
reported pKb of VI (i.e., 5.5–6.1) [26]. The remaining organic solvent was eliminated by evaporation
under continuous stirring overnight, and the resultant NPs were stored at 4 ◦C.
2.3.2. Characterization of NPs
Hydrodynamic properties were optimized as a function of final volume (VF = 10 mL, 20 mL and
30 mL) and final concentration ([NPs]F = 1 mg/mL and 5 mg/mL), and the evolution of hydrodynamic
properties of NPs was evaluated as a function of pH and time after freeze-drying and resuspension
(Supporting Information). Particle size distribution and zeta potential (ξ) were determined by dynamic
light scattering (DLS) and laser Doppler electrophoresis (LDE), respectively, using a Malvern Nanosizer
NanoZS Instrument equipped with a 4 mW He-Ne laser (λ = 633 nm) at a scattering angle of 173◦.
Measurements were performed at 25 ◦C. For each sample, the statistical average and standard deviation
of data were calculated from 3 measurements of 11 runs each, one in case of hydrodynamic diameter
(Dh) and polydispersity (PdI) and 3 measurements of 20 runs each, one in case of ξ. SEM analysis of
KT NPs was performed with a Hitachi SU8000 TED, cold-emission FE-SEM microscope working with
an accelerating voltage 1 kV-D (see Supporting Information for more details).
2.3.3. Dexamethasone and Coumarin-6 Encapsulation
Dexamethasone (Dx, Aldrich, ≥98% pure; CAS Number: 50-02-2)-loaded NPs and coumarin-6
(c6)-loaded NPs were prepared by the described nanoprecipitation method with slight modifications.
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Dx (5%, 10%, 15%, or 20% w/w with respect to the polymer) or c6 (Aldrich, 1% w/w with respect to
the polymer), and the corresponding polymer were dissolved in a mixture of acetone:ethanol (80:20,
v/v) and slowly dropped into the aqueous buffer solution (0.1 M Acetic Acid, 0.1 M NaCl) at pH 4
under magnetic stirring. NPs (3 mg/mL) were dialyzed against the same buffer for 72 h to eliminate
remaining organic solvents and the soluble non-entrapped Dx or c6. The resultant NPs were filtered
through 1 µm Nylon filters (Whatman Puradisc) to eliminate insoluble Dx or c6
2.3.4. Encapsulation Efficiency (%EE) and Loading Capacity (%LC)
The powder resulting from freeze-drying of Dx-loaded NPs and c6-loaded NPs was dissolved in
2 mL of acetone:ethanol (80:20, v/v). This led to the disassembly of nanoparticle structure and release
of the encapsulated drug. After organic solvent evaporation overnight, the copolymer-Dx mixture
and the copolymer-c6 mixture were dissolved in acetonitrile:water (80:20, v/v) or ethanol, respectively,
to precipitate the polymer. Centrifugation at 10,000 rpm for 5 min at RT separated the NPs pellet
from the Dx and c6-containing supernatant, which were analyzed by HPLC (Dx, λabs = 239 nm) and
UV spectrophotometry (c6, λabs = 459 nm), correspondingly. Encapsulation efficiency (%EE) was
computed using Equation (1) and the loading capacity (%LC) using Equation (2). According to this,
NPs were labeled as XY-KT NPs being X the encapsulation efficacy and Y the drug or dye encapsulated.




Loading capacity (%) =
mass o f Dx/c6 measured
mass o f NPs
× 100 (2)
2.4. Cell Culture
RAW264.7 murine macrophages (Sigma-Aldrich) were cultured in high-glucose Dulbecco’s
modified Eagle’s medium (DMEM; Sigma, Saint Louis, MO, USA) supplemented with 10% (v/v) fetal
bovine serum (FBS; Gibco, BRL), 2% (v/v) L-Glutamine (Sigma, Saint Louis, MO, USA), and 1% (v/v)
Penicillin-G (Sigma, Saint Louis, MO, USA) at 37 ◦C, 5% CO2, and 90% relative humidity.
2.4.1. Uptake Rate of c6-Loaded KT NPs by RAW264.7 Macrophages
RAW264.7 cells were seeded into 6-well plates (1.7 × 105 cells/mL) in complete DMEM. The
cells were incubated overnight. The medium was replaced with the corresponding c6-loaded KT
NPs suspension in DMEM (NPs:DMEM (1:5, v/v), Figures S1 and S2) that was added. Cells were
incubated with NPs over different times 1, 2, 4, 6, 8, and 24 h at 37 ◦C. At each time point, cells
were washed with cold PBS, harvested, and counted to normalize fluorescence/cell. Then, they
were centrifuged at 10,000 rpm, the supernatant was discarded, and cell’s pellet was lysed with
ethanol. At this point, ethanol compromised the nanoparticle structure releasing and dissolving
internalized c6. After further centrifugation at 10,000 rpm, fluorescence of supernatant was measured
(458/540 nm, excitation/emission) by a Multi-Detection Microplate Reader Synergy HT (BioTek
Instruments; Winooski, VT, USA).
2.4.2. Route of Nanoparticle Internalization
RAW264.7 macrophages, cells were preincubated with chlorpromazine (CHL; 50 µM,
Sigma-Aldrich) to inhibit clathrin-mediated endocytosis, nystatin (NYST; 10 µg/mL, Sigma-Aldrich)
to inhibit caveolae-mediated endocytosis, and amiloride (AMI; 100 µM, Sigma-Aldrich) to inhibit
macropinocytosis. After 30 min at 37 ◦C, the inhibitor solutions were removed, and freshly prepared
c6-loaded KT NPs in medium (NPs:DMEM (1:5, v/v)) were added (0.25 mg/mL) and further incubated
for another 8 h. Subsequently, the cells were washed and lysed as previously described. The groups
treated with c6-loaded NPs but without inhibitor at 4 ◦C or at 37 ◦, were used as negative and positive
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control, respectively. The percentage uptake after treatment with the inhibitors was normalized to the





2.4.3. In Vitro Cytotoxicity Assay of NPs
In a 96-well plate under permissive conditions, 2 × 105 live cells/mL (100 µL/well) were seeded.
After 24 h, cells were treated with different concentrations of NPs suspension (0.250, 0.125, 0.090,
0.045, 0.023, or 0.011 mg/mL; NPs:DMEM (1:5, v/v)), and after 24 h, cell viability was determined
by AlamarBlue (Invitrogen) assay. Absorbance at 570 nm was measured using a Multi-Detection
Microplate Reader Synergy HT (BioTek Instruments, Winooski, VT, USA). The treatments were done in
replicates (n = 8). Results were expressed as % of cell viability with respect to the control (cells treated
with medium).
2.4.4. Nitric Oxide (NO) Assay
RAW264.7 macrophages were seeded in a 96-well plate (2 × 105 live cells/mL, 100 µL/well). After
24 h, cells were treated with lipopolysaccharide (LPS; CAS Number: 297-473-0, Sigma-Aldrich; 5 µg/mL)
and with different [NPs]F of KT NPs, 14Dx-KT NPs, or free Dx. After 24 h and 48 h of treatment, NO
released by macrophages was determined using Griess reagent modified kit (Sigma-Aldrich) according
to the manufacturer instructions. The treatments were done in replicates (n = 8), and results were
expressed as mean ± standard deviation of the percentage of NO released with respect to the control
(LPS-activated cells with no further treatment or inflammatory conditions untreated (IC,U)).
2.4.5. RNA Extraction, Reverse Transcription, Real-Time Quantitative PCR (RT-qPCR)
The transcript levels of M1- (Il12b, Il23a, and Tnfa) and M2- (Tgfb1, Il10, and Vegfa) related genes
were determined by quantitative RT-PCR. RAW264.7 cells were incubated 24 h with culture medium
(non-inflammatory conditions, NIC) or with LPS (5 µg/mL) to simulate inflammatory conditions (IC,U),
and either non-treated or treated with unloaded KT-NPs (0.045 mg/mL; NPs:DMEM (1:5, v/v)), 14Dx-KT
NPs (5.1 µM Dx and 0.045 mg/mL NPs; NPs:DMEM (1:5, v/v)), or free Dx (5.1 µM). Media were collected
after 24 h of treatment to eliminate non-internalized NPs or free Dx, and cells were further incubated
in culture medium up to 7 days. Culture medium was refreshed every 48 h. Total RNA was extracted
from cells after 1 and 7 days of NPs addition. PureLink RNA Mini Kit (Applied Biosystems, Foster City,
CA, USA) was used for this purpose following manufacturer’s instructions [27]. RNA concentration
was quantified by measuring absorbance at 260 and 280 nm in a NanoDrop 1000 spectrophotometer
(Thermo Scientific) and 40 ng RNA/sample were transformed into cDNA using a MultiScribe reverse
transcription-based reaction kit (Applied Biosystems) in the presence of an RNAse inhibitor (N8080119,
Applied Biosystems) in a MyCycler thermocycler (Bio-Rad; with the following temperature profile:
25 ◦C—10 min, 37 ◦C—2 h, 85 ◦C—5 min, 4 ◦C—∞). Table S1 shows the list of specific primers used
for quantitative PCR (all from Sigma). The reaction was performed using the Power SYBR Green
PCR Master Mix (Applied Biosystems), in an ABI PRISM 7900HT Real-Time PCR System (Applied
Biosystems with the following temperature profile: 95 ◦C—15 s, 60 ◦C—60 s, 40 cycles). Melting
curves were generated in order to verify the specificity of the amplification (15 s, from 60 ◦C to 95 ◦C).
RT-qPCR expression data were analyzed according to the 2−∆∆Ct method (Livak et al., 2001) or as 2−∆Ct
normalized to β-actin, and array views were generated using MeV software.
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3. Results and Discussion
3.1. Methacrylic Derivative of Ketoprofen Monomer (HKT)
A methacrylic derivative of ketoprofen was synthesized with yields above 90% and high purity
as confirmed by 1H-NMR spectroscopy (Figure 1a). KT was linked through the carboxylic group,
the main contributor to gastrointestinal adverse effects, to HEMA, forming an ester bond which is
susceptible to hydrolysis under acidic conditions and/or by esterases. pH values between 5.5 and 6.0
and high esterase concentration are encountered in the lumen of lysosomes [28]. Altogether, this may
provide a pH/enzyme-accelerated release of KT at inflamed areas where pH values are around 6.4 [29],
or in the lumen of lysosomes after sequestration by inflammatory cells.
3.2. Synthesis and Characterization of Copolymer of Ketoprofen-Based Methacrylic Monomer and 1-Vinyl
Imidazole, Poly(HKT-co-VI)
The disappearance of the 1H-NMR vinyl proton signals of HKT and VI (CH2-VI between 4.5 and 5.0
ppm and CH2-HKT between 5.0 and 6.0 ppm), the new 1H-NMR signals resultant from the methylene
protons of the backbone chains (CH3-m, CH2-l, and CH2-n between 0.1 and 2.8 ppm), and the broadening
of the signals as a result of the macromolecular nature of the copolymer (Figure 1b) confirmed the
successful co-polymerization, at established initial conditions (FHKT = 0.4 and [M] = 0.5 M), of
hydrophobic HKT, and hydrophilic VI was carried out by free radical polymerization (yield = 84%).
The copolymers molar composition was quantitatively determined from their corresponding
1H-NMR spectra by considering the signals between 0.1 and 2.8 ppm assigned to eight protons of HKT
(CH3-k, CH3-o, and CH2-n) and two protons of VI (CH2-1) and the signals between 6.5 and 8.0 ppm
resultant from nine aromatic protons of HKT (CH-a-i) and three aromatic protons of VI (CH-3,4,5). The
differences among copolymer HKT molar content (FHKT) and feed HKT molar content (fHKT) are
explained by the two orders of magnitude difference in the reactivity ratios of the monomers (Figure S3)
and the fact that total conversion was not reached. The molecular weight (Mw) of the copolymer was
99 KDa, with polydispersity index values of 2.3 that correspond to those obtained from a conventional
radical polymerization reaction. The copolymer presented a unique glass transition temperature
(Tg = 54 ◦C) indicating that no-phase segregation was observed, although a pseudo-block copolymer
structure was obtained according to reactivity ratios.
3.3. Preparation and Characterization of Self-Assembled Nanoparticles
The aforementioned pseudo-block microstructure and the hydrophobic–hydrophilic balance
provided the copolymers with the necessary properties for self-assembling by nanoprecipitation. NPs
presented a hydrophobic core mainly formed by covalently linked KT and a hydrophilic shell mainly
formed by VI. Nanoprecipitation method was performed as previously described, and NPs were
labeled as KT NPs. SEM micrograph of the NPs confirmed the successful NPs’ formation presenting
spherical shape, slight polydispersity in size, and diameter of about 100 nm (Figure S4). Regarding
hydrodynamic properties, a positive ξ value of +30 ± 1 mV was obtained, confirming the presence of
VI protonable amine groups on the surface of the NPs and, according to literature, an indication of
good stability in suspension [30]. They presented Dh of 117 ± 1 nm with low PdI values (0.139 ± 0.004).
The spherical morphology, positive surface charge and diameters between 100 and 200 nm made KT
NPs suitable for accumulation at inflamed areas [31,32] as well as for an improved sequestration by
inflammatory cells avoiding lymphatic drainage [33,34]. The diameter or surface charge of KT NPs did
not significantly vary with the different final concentration on the aqueous phase or final volumes
under study. Within the studied ranges, the key variable was the concentration of copolymer in the
organic phase, which, when increased, led to NPs with 50 nm larger diameter (Table 1). Finally, in
order to explore the most suitable conditions for NPs storage, a pH study, stability in suspension
study, and freeze-drying study were performed. Figure 2a shows the size distribution and the ξ
values of the KT NPs at different pH values (i.e., 4.0, 4.5, 5.0, and 5.5). At pH 5.5, a broadening
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of the size distribution curve and an increase in the intensity of the peak in the microscale, which
might correspond to agglomerated NPs, were observed. A decrease in surface charge was observed
as pH increases due to deprotonation of amine groups of VI as the pH approaches to the pKb of VI
(pKb = 5.0–6.0). The reduction in the electrostatic repulsion between particles caused NPs aggregation.
Therefore, the synthesis was carried out at pH 4 (0.1 M acetic acid) to ensure the protonation of VI and
the good stability of the NPs over time. Figure 2b shows that, under these conditions, there were no
significant changes in the hydrodynamic properties of KT NPs at 0 days, 14 days, and 28 days when
stored at 4 ◦C. Furthermore, NPs recovered their initial hydrodynamic properties after freeze-drying
and dispersion in the buffer solution at pH 4.0 when sonicated for 10 min with an ultrasound tip (30%
amplitude) (Figure 2c). Therefore, NPs can be stored in powder or in suspension at pH 4.0 and 4 ◦C for
at least one month.
Table 1. Hydrodynamic properties (i.e., hydrodynamic diameter (Dh), polydispersity of size distribution
(PdI), and zeta potential (ξ)) of KT NPs at a different final concentration of nanoparticles in the aqueous
phase ([NPs]A.P.) and at different final volumes (VF).
[NPs]A.P. a VF (mL) [HKT48]O.P. b Dh c (nm) PdI d ξ e (mV)
1.0 mg/mL
10 10 mg/mL 117 ± 1 0.139 ± 0.004 +29 ± 1
20 10 mg/mL 119 ± 3 0.153 ± 0.018 +29 ± 1
30 10 mg/mL 116 ± 1 0.142 ± 0.027 +30 ± 1
5.0 mg/mL
10 10 mg/mL 115 ± 1 0.124 ± 0.008 +30 ± 1
20 10 mg/mL 119 ± 1 0.112 ± 0.013 +31 ± 1
30 15 mg/mL 163 ± 3 0.186 ± 0.021 +29 ± 1
a Final concentration of nanoparticles (NPs) in the aqueous phase, b concentration of copolymer in the organic
phase, c mean hydrodynamic diameter. and d polydispersity of the size distribution obtained by dynamic light
scattering (DLS), e mean zeta potential obtained by laser Doppler electrophoresis (LDE).Pharmaceutics 2020, 12, x FOR PEER REVIEW 9 of 19 
 
 
Figure 2. Size distribution (by intensity) and z-potential (ξ) of ketoprofen (KT) NPs measured (a) at 
different pH values or at pH 4.0; (b) at day 0 and after 28 days stored at 4 °C; and (c) before freeze-
drying (dashed line) and after freeze-drying and tip sonication for 10 min. 
3.4. Dexamethasone and Coumarin-6 Encapsulation 
NPs were labeled as XY-KT NPs, with X being the encapsulation efficacy, and Y the drug or dye 
encapsulated. To achieve the maximum final concentration of Dx in our systems, we performed a 
screening of different w/w percentages with respect to the copolymer (5% w/w, 10% w/w, 15% w/w, 
and 20% w/w), and the final mass of Dx encapsulated was computed by HPLC (Figure S3). The 
formulation with 15% w/w of Dx with respect to the copolymer was chosen for further experiments 
as it reached the highest Dx %EE and %LC (14% and 3.85%, respectively). The amount of drug 
encapsulated correlated with an increase in Dh of the NPs (140 ± 1 nm) and a reduction of the PdI 
value (0.081 ± 0.010). However, no significant differences were observed in ξ values (+29 ± 1 mV). 
Interestingly, for a given concentration, the newly synthesized KT NPs encapsulated twice the 
amount of Dx than their NAP-bearing homologs [11], which might contribute to an improved anti-
inflammatory effect. Coumarin-6 (c6) was used as a fluorescent probe in NPs internalization cellular 
studies. The dye was encapsulated at a low % w/w (i.e., 1% w/w) to avoid fluorescence quenching. 
Table 2 summarizes the hydrodynamic properties and zeta potential of Dx-loaded, c6-loaded, and 
unloaded KT NPs. 
  
Figure 2. Size distribution (by intensity) an z- i l (ξ) of ketoprofen (KT) NPs measured (a) at
different pH values or at pH 4.0; (b) at d y 0 and after 28 days stored at 4 ◦C; and (c) befor fr ez -drying
(dashed line) and after freeze-drying and tip sonication for 10 min.
Pharmaceutics 2020, 12, 723 9 of 18
3.4. Dexamethasone and Coumarin-6 Encapsulation
NPs were labeled as XY-KT NPs, with X being the encapsulation efficacy, and Y the drug or dye
encapsulated. To achieve the maximum final concentration of Dx in our systems, we performed a
screening of different w/w percentages with respect to the copolymer (5% w/w, 10% w/w, 15% w/w,
and 20% w/w), and the final mass of Dx encapsulated was computed by HPLC (Figure S5). The
formulation with 15% w/w of Dx with respect to the copolymer was chosen for further experiments
as it reached the highest Dx %EE and %LC (14% and 3.85%, respectively). The amount of drug
encapsulated correlated with an increase in Dh of the NPs (140 ± 1 nm) and a reduction of the PdI
value (0.081 ± 0.010). However, no significant differences were observed in ξ values (+29 ± 1 mV).
Interestingly, for a given concentration, the newly synthesized KT NPs encapsulated twice the amount
of Dx than their NAP-bearing homologs [11], which might contribute to an improved anti-inflammatory
effect. Coumarin-6 (c6) was used as a fluorescent probe in NPs internalization cellular studies. The dye
was encapsulated at a low % w/w (i.e., 1% w/w) to avoid fluorescence quenching. Table 2 summarizes
the hydrodynamic properties and zeta potential of Dx-loaded, c6-loaded, and unloaded KT NPs.
Table 2. Summary of encapsulation efficiency (%EE), loading capacity (%LC), and hydrodynamic
properties (i.e., mean hydrodynamic diameter (Dh), polydispersity of size distribution (PdI), and zeta
potential (ξ)) of newly prepared KT NPs, 14Dx-KT NPs, and 47c6-KT NPs.
Sample % EE a % LC b Dh c (nm) PdI d ξ e (mV)
KT NPs - - 117 ± 1 0.139 ± 0.004 +30 ± 1
14Dx-KT NPs 14 3.85 140 ± 1 0.081 ± 0.010 +29 ± 1
47c6-KT NPs 47 0.47 126 ± 2 0.154 ± 0.021 +32 ± 2
a Percentage of encapsulation efficiency of coumarin-6, b percentage of loading capacity of coumarin-6, c mean
hydrodynamic diameter, and d polydispersity of the size distribution obtained by DLS, e mean zeta potential
obtained by LDE.
3.5. Uptake Rate of c6-Loaded NPs by RAW264.7 Macrophages
A fast uptake of NPs by inflammatory cells is crucial for retention at inflamed areas [11], and the
route by which they are internalized determines their fate inside the cell [35]. Fluorescent c6-loaded
NPs were prepared as described before. They were used to monitor NPs internalization by RAW264.7
macrophages over 24 h of exposure at 37 ◦C (Figure 3a). Figure 3a shows the mass of c6 internalized per
cell at different time points (i.e., 1, 2, 4, 6, 8, and 24 h). The uptake rate of NPs was linearly increasing up
to 24 h without reaching a plateau, an indication of rapid internalization. However, it was important
to differentiate the possible surface adsorption of cationic nanoparticles on the negatively charged cell
membrane from actual internalization. To do that, the uptake study was conducted at 4 ◦C, relying
on the decreased membrane recycling occurring at this temperature [36]. The cellular uptake was
negligible when incubated at 4 ◦C in comparison to uptake at 37 ◦C (Figure 3b), demonstrating the
energy-dependent internalization of NPs. The endocytic pathways involved in the cellular uptake
of the system were investigated, employing endocytic inhibitors of the main routes used by cationic
nanomedicines to enter cells: chlorpromazine (CHL, clathrin-dependent endocytosis), amiloride
(AMI, macropinocytosis), and nystatin (NYST, caveolae-mediated endocytosis) (Figure 3b) [35]. When
treated with CHL, cellular uptake of KT NPs was reduced by 36 ± 2% (p < 0.05) with respect to the
untreated positive control (37 ◦C), respectively. Additionally, pre-treatment AMI led to the reduction
of internalization of NPs by 48 ± 3% (p < 0.05) relative to the positive control. However, no significant
differences were observed after NYST pre-treatment. These results indicated that KT NPs internalization
mainly occurred by clathrin-mediated endocytosis (CME) and macropinocytosis. These results correlate
with reports of positively charged nanoparticles of ~100 nm diameter predominantly internalized
through CME mechanism [37] and those claiming that the electrostatic interactions with the negatively
charged cell membrane facilitate cationic molecules internalization through macropinocytosis [23].
Internalization via CME and/or macropinocytosis is recognized to be a more destructive pathway
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compared to caveolae-mediated endocytosis [23,35]. Vesicle acidification and fusion with lysosomes
occurring during CME and macropinocytosis might facilitate the release of both drugs due to the
enhanced susceptibility of the ester bond to be degraded at acidic pH and in the presence of esterases.
Therefore, the covalent ester bond that links KT to the polymeric backbone will be degraded, and the
NPs self-assembled structure will be disrupted.
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3.6. In Vitro Cytotoxicity Assay of NPs
Cytotoxicity of free Dx (the concentration corresponds to the maximum concentration encapsulated
in the NPs), 14Dx-KT NPs, and unloaded KT NPs was tested using murine macrophages (RAW264.7) as
model inflammation-related cells. Figure 4 shows the cell viability compared to a control of untreated
cells (i.e., non-inflammatory conditions, NIC). None of the concentrations tested were cytotoxic after
24 h, as cell viability was always higher than 70%, and for concentrations above 0.25 mg/mL, it was
never below 85% (ISO 10993-5:2009). There were no statistically significant differences (* p < 0.05)
between Dx-loaded and unloaded NPs (i.e., 14Dx-KT NPs and KT NPs) or between free Dx and
14Dx-KT NPs at any of the tested concentrations.
Pharmaceutics 2020, 12, 723 11 of 18Pharmaceutics 2020, 12, x FOR PEER REVIEW 2 f 19 
 
 
Figure 4. Cell viability of RAW264.7 macrophages treated with different concentrations of unloaded 
KT NPs (black), 14Dx-KT NPs (dashed white), or free Dx (red) over 24 h. The diagrams include the 
mean, the standard deviation (n = 8), and the ANOVA results (* p < 0.05 statistically significant 
difference with cells under non-inflammatory conditions (NIC) and between the different systems). 
3.7. Effect of Polymeric Nanoparticles Based on Ketoprofen and Dexamethasone on Macrophage NO Levels 
Anti-inflammatory capacity of the systems after 24 h and 48 h was assessed by measuring the 
levels of nitric oxide (NO) released by lipopolysaccharide (LPS)-activated macrophages. When 
RAW264.7 cells are activated by LPS, they polarize to their pro-inflammatory phenotype (M1) and 
they start overproducing NO, a well-known inflammatory mediator [38]. NO released was measured 
after 24 h (Figure 5a,b, black) and 48 h (Figure 5a,b, dashed white) of incubation with LPS and either 
KT NPs (Figure 5a) or 14Dx-KT NPs (Figure 5b) at different concentrations. KT NPs significantly (# p 
< 10−5) improved reduced NO release after 48 h when compared to 24 h, whereas NO levels were 
maintained overtime with 14Dx-KT NPs. This result indicated the faster anti-inflammatory effect of 
Dx-loaded NPs, which was physically entrapped, allowing an earlier release when compared to the 
covalently linked NSAID. Moreover, Figure 5c presents LPS-induced NO release after 48 h of LPS 
administration and challenging with different concentrations of unloaded KT NPs (black) 14Dx-KT 
NPs (dashed white) or free Dx (red). After 48 h of incubation, all systems counteracted LPS-induced 
NO release in a statistically significant manner for all concentrations tested (# p < 10–5) with respect to 
LPS treated cells (IC,U). 
Figure 4. Cel viability of RAW264.7 macrophages treated with different con e trations of unloaded KT
NPs (black), 14Dx-KT NPs (da hed white), or free Dx (red) ov r 24 h. The diagrams include the mean,
the standard deviation (n = 8), a d the ANOVA results (* p < 0.05 statistically significant difference
with c lls under non-inflammatory conditions (NIC) and between the differe systems).
3.7. Effect of Polymeric Nanoparticles Based on Ketoprofen and Dexamethasone on Macrophage NO Levels
Anti-inflammatory capacity of the systems after 24 h and 48 h was assessed by measuring the levels
of nitric oxide (NO) released by lipopolysaccharide (LPS)-activated macrophages. When RAW264.7
cells are activated by LPS, they polarize to their pro-inflammatory phenotype (M1) and they start
overproducing NO, a well-known inflammatory mediator [38]. NO released was measured after 24 h
(Figure 5a,b, black) and 48 h (Figure 5a,b, dashed white) of incubation with LPS and either KT NPs
(Figure 5a) or 14Dx-KT NPs (Figure 5b) at different concentrations. KT NPs significantly (# p < 10−5)
improved reduced NO release after 48 h when compared to 24 h, whereas NO levels were maintained
overtime with 14Dx-KT NPs. This result indicated the faster anti-inflammatory effect of Dx-loaded
NPs, which was physically entrapped, allowing an earlier release when compared to the covalently
linked NSAID. Moreover, Figure 5c presents LPS-induced NO release after 48 h of LPS administration
and challenging with different concentrations of unloaded KT NPs (black) 14Dx-KT NPs (dashed
white) or free Dx (red). After 48 h of incubation, all systems counteracted LPS-induced NO release in a
statistically significant manner for all concentrations tested (# p < 10–5) with respect to LPS treated
cells (IC,U).
Results demonstrated that NO reduction capacity was maintained after 48 h at any of the
concentrations tested in case of KT-based systems. Moreover, Dx-loaded systems performed better
than free Dx at specific concentrations of KT-based systems (* p < 0.05; [NPs] = 0.045 mg/mL and
0.023 mg/mL). One of these concentrations, 0.045 mg/mL, was chosen for further RT-qPCR analysis as
it was the maximum concentration of NPs with improved reduction of NO released levels and it will
allow comparison with RT-qPCR results obtained for previously described NAP-based systems. Again,
KT-based systems showed an improved behavior when compared to previously described NAP-based
systems in terms of reduction of NO released levels at any of the two time points tested, especially
Dx-loaded systems [11]. This might be attributed to the higher content in Dx (5.1 µM and 2.55 µM,
respectively) and to the faster internalization of KT-based NPs.
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Figure 5. NO release by RA 264.7 macrophages after 24 h (black) and 48 h (dashed white) with no
treatment (NIC), treatment with LPS alone (IC,U), and treatment with LPS and different concentrations
of (a) unloaded KT NPs and (b) 14Dx-KT NPs; (c) NO release after 48 h with no treatment (NIC),
treatment with LPS (IC,U), and treatment with LPS and different concentrations of loaded NAP NPs
or KT NPs (black), 8Dx-NAP NPs or 14Dx-KT NPs (dashed white), or free Dx (red). The diagrams
include the mean, the standard deviation (n = 8), and the ANOVA results (* p < 0.05, *** p < 10−3, and
# p < 10−5 statistically significant difference with IC,U cells or between 24 h and 48 h time points).
3.8. Real-Time PCR Analysis of the Expression of M1-M2 Specific Reference Genes after NPs Treatment in
Non-Stimulated Macrophages and LPS-Stimulated Macrophages
A high positive surface charge of NPs has been reported as one of the external stimulus leading to
M1 polarization of macrophages [39,40]. Because of this, the effect of cationic polymeric NPs based on
ketoprofen and dexamethasone on M1-related gene transcript levels was studied in non-stimulated
RAW264.7 cells (NIC) to analyze whether these NPs induce to some extent an M1 polarization. Figure 6
shows the transcript levels of Tnfa, Il12b, and Il23a determined by RT-qPCR after 1 day and 7 days
of treatment with KT NPs (0.045 mg/mL) and 14Dx-KT NPs (5.1 µM Dx and 0.045 mg/mL NPs), and
free Dx (5.1 mM). Results were expressed relative to the corresponding level of expression of each
transcript in the untreated sample (i.e., non-inflammatory conditions, NIC). Figure S6 shows heat maps
and Table S2 numerical RT-qPCR data. Figure 6 shows that there was no significant overexpression of
M1 markers with respect to the control (NIC) after 1 day or 7 days of treatment with 14Dx-KT NPs;
whereas after KT NPs treatment, only Il12b was slightly overexpressed after 1 day of treatment. These
data de onstrated that, although there was a slight activation of M1 marker genes, there were no
significant long-term M1-polarization after treatment with cationic KT-based NPs.
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and 0.045 mg/mL NPs). The expression of M1 and M2 (Figure 7) marker genes was presented relative 
to their corresponding levels in the untreated sample (NIC). Regarding M1 markers, when compared 
to basal cellular levels (NIC), LPS-treatment (IC,U) significantly increased transcript levels of Tnfa 
after 1 day of treatment and Il12b after 7 days of treatment, and it had no effect on Il23a. The short-
term induction of Tnfa was reversed by all systems tested. However, after 7 days of treatment free of 
Dx and KT NPs did not affect the expression of Tnfa, while the system combining both (14Dx-KT 
NPs) induced a significant increase in expression of this gene. This might be occurring because of the 
PGE2 reduction after NSAID/GC combined treatment as both the GC and the NSAID contributed to 
reducing PGE2 levels [41]. Regarding Il12b expression, although 14Dx-KT NPs treatment caused the 
increase of Il12b transcript levels after 1 day of treatment, all systems reversed the LPS-induced 
overexpression after 7 days of treatment, which was more significant in free Dx and Dx-loaded NPs. 
Moreover, 14Dx-KT NPs and KT NPs induced a slightly significant overexpression of Il23a with 
Figure 6. Quantitative real-time PCR data. Graphical presentation of gene transcript levels of
M1 markers in non-LPS-activated samples (non-inflammatory condition, NIC) treated with free
dexamethasone (free Dx, 5.1 µM, red), Dx-loaded ketoprofen-bearing NPs (14Dx-KT NPs, 5.1 µM Dx,
and 0.045 mg/mL NPs, white) and unloaded ketoprofen-bearing NPs (KT NPs, 0.045 mg/mL, black)
for 1 day (plain) and 7 days (dashed). Results are expressed relative to the corresponding level of
expression of each transcript in the untreated sample. The diagrams include the mean, the standard
deviation (n = 2), and the ANOVA results (*—comparison with untreated NIC control, * p < 0.05,
** p < 0.01, *** p < 0.001 and **** p < 0.0001).
Then, in a second set of experiments, the anti-inflammatory effect of the systems was analyzed
under inflammatory conditions. RAW264.7 macrophages were cultured in the presence of LPS to
mimic pro-inflammatory conditions and treated with either culture media (inflammatory conditions,
untreated (IC,U)), free Dx (5.1 µM), unloaded KT NPs (0.045 mg/mL) or 14Dx-KT NPs (5.1 µM Dx and
0.045 mg/mL NPs). The expression of M1 and M2 (Figure 7) marker genes was presented relative to their
corresponding levels in the untreated sample (NIC). Figure S7 shows heat maps and Table S2 numerical
RT-qPCR data. Regarding M1 markers, when compared to basal cellular levels (NIC), LPS-treatment
(IC,U) significantly increased transcript levels of Tnfa after 1 day of treatment and Il12b after 7 days of
treatment, and it had no effect on Il23a. The short-term induction of Tnfa was reversed by all systems
tested. However, after 7 days of treatment free of Dx and KT NPs did not affect the expression of
Tnfa, while the system combining both (14Dx-KT NPs) induced a significant increase in expression
of this gene. This might be occurring because of the PGE2 reduction after NSAID/GC combined
treatment as both the GC and the NSAID contributed to reducing PGE2 levels [41]. Regarding Il12b
expression, although 14Dx-KT NPs treatment caused the increase of Il12b transcript levels after 1 day
of treatment, all systems reversed the LPS-induced overexpression after 7 days of treatment, which
was more significant in free Dx and Dx-loaded NPs. Moreover, 14Dx-KT NPs and KT NPs induced a
slightly significant overexpression of Il23a with respect to the LPS-treated control that was reversed
after 7 days of treatment. Therefore, in the long term, Tnfa overexpression was accompanied by normal
levels of Il12b and Il23a. These findings correlate with the described dual role of Tnfa: as an initiator of
inflammatory response early in the infection and selective regulator of inflammatory response in the
later stages of inflammation [42].
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5.1 µM, red), Dx-loaded k toprofen-bearing NPs (14Dx-KT NPs, 5.1 µM Dx and 0.045 mg/mL NPs,
white), and unloaded ketoprofen-bearing NPs (KT NPs, 0.045 g/mL, black) for 1 day (plain) or 7 days
(dashed). Results were xpressed relative to the corresponding level of expres ion of each transcript in
no -i flammatory conditions (RAW264.7 alone, NIC). The diagrams include the mean, the standard
deviation (n = 2), and the ANOVA results (#—comparison with IC,U control, # p < 0.05, # p < .01, and
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Regarding M2 markers, LPS-treat e t i Il10 expre sion in the short term, while
it nhib ted it after 7 days of treat ent. , ression was not affected in the short term
but significantly repressed after 7 days of treat t. is long-term effect on Tgfb1 expression was
significantly reversed by all treat ents. On the contrary, the addition of 14Dx-KT NPs produced
a significant increase in Il10, Tgfb1, and Vegfa expression with respect to +LPS conditions at both
time-points tested. Interestingly, all systems maintained the overexpression of Il10 in time, something
that did not occur in simulated inflammatory conditions. Il10 is considered the most important
anti-inflammatory cytokine in humans [43], confirming the anti-inflammatory capacity of the systems.
These data indicated that KT NPs presented a potent anti-inflammatory behavior improving that of the
previously described NAP-based analog. This result was expected as KT is a more potent NSAID than
NAP in terms of COX inhibition [21,22]. Finally, regarding the synergistic Il12b, gene repression was
not observed, meaning that the combination of Dx with a stronger COX-inhibitor did not imply a more
potent synergistic effect. This result suggested that the COX inhibition was not contributing to the
synergistic Il12b gene repression in murine macrophages when combining NAP and Dx. Moreover, this
synergistic repression was observed for the NAP/Dx system even in non-LPS-activated macrophages
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in which COX was not overexpressed. All these data indicate that the COX-dependent route does
not play a key role in the synergistic effect observed, and further studies on the mechanism of action
should focus on MAPK pathways and 5-LO metabolism as there are reports of modulation of Il12b
expression in antigen-presenting cells (i.e., macrophages and dendritic cells, mainly) through these
pathways [13–17].
4. Conclusions
Anti-inflammatory NPs that combine KT (covalently attached) and Dx (physically entrapped)
were successfully prepared, and their biological activity was evaluated. The amount of Dx entrapped
by KT-bearing polymer drugs into NPs was optimized by testing different %Dx (w/w, with respect to
the copolymer) in such a way that the amount of Dx encapsulated was maximized. Moreover, it was
demonstrated that the spherical shape, the hydrodynamic properties, and positive surface charge of KT
NPs (Dh = 100–200 nm, PdI below 0.2, and ξ close to +30 mV) translated into rapid internalization by
macrophages through CME and macropinocytosis, two internalization routes that might facilitate the
enzymatic and pH-mediated release of KT and Dx in the lysosome. 14Dx-KT NPs and unloaded KT
NPs reduced LPS-induced NO release when compared to the control, with the Dx-loaded system more
effective at 24 h due to the early release of the physically entrapped Dx. Moreover, the unloaded KT NPs
were able to reduce to almost basal levels (NIC) the expression of all M1 markers tested. The RT-qPCR
analysis also concluded that the synergistic inhibition of Il12b was not occurring in a significant manner
for 14Dx-KT NPs. However, long-term treatment with 14Dx-KT NPs led to Tnfa overexpression and
regulation of Il12b and Il23a expression, reducing it up to normal cellular levels. As a conclusion,
the KT-based systems described in this paper present interesting anti-inflammatory activity as they
reduced NO released levels and M1 markers expression while increasing M2 markers expression under
inflammatory conditions. Moreover, KT-based systems were rapidly internalized by macrophages,
which might favor the retention at inflamed areas through the ELVIS effect. Therefore, they could be
used by themselves, as well as encapsulating Dx or other hydrophobic drugs, for the treatment of
inflammatory processes. Moreover, it was demonstrated that the use of a KT, an NSAID with more
potent COX-inhibitory activity did not cause synergistic repression of Il12b gene when combined with
Dx. This, together with the fact that this synergistic repression was observed for the NAP/Dx system
even in non-LPS-activated macrophages in which COX was not overexpressed [11], indicated that the
COX-dependent route was not crucial for the synergy observed. Therefore, further studies should be
done on NAP/Dx mechanism of action focusing on MAPK pathways and 5-LO metabolism.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/12/8/723/s1,
Figure S1. Color and pH values of nanoparticles (KT NPs, 3 mg/mL) in suspension at different NPs:DMEM
volume ratios; Figure S2. Hydrodynamic properties (i.e., diameter (size) in nanometers, polydispersity (PdI)
and, zeta potential (ξ) in mV of nanoparticles (KT NPs, 3 mg/mL) in suspension at different NPs:DMEM volume
ratios; Figure S3, Surface diagrams representing the variation of the instantaneous molar fraction of HKT in the
copolymer; Figure S4, Scanning Electron Microscopy micrograph showing morphology of KT NPs; Figure S5, Mass
of dexamethasone encapsulated measured by HPLC for each initial %Dx (w/w) with respect to poly(HKT-co-VI)
copolymer. Results represent mean ± SD of two independent experiments, n = 2, * p ≤ 0.05; Figure S6, Quantitative
real-time PCR data. Heat map of gene transcript levels of M1 markers in non-LPS activated samples (NIC) treated
with free dexamethasone (free Dx, 5.1 µM, red), Dx-loaded ketoprofen-bearing NPs (14Dx-KT NPs, 5.1 µM Dx, and
0.045 mg/mL NPs, white) and unloaded ketoprofen-bearing NPs (KT NPs, 0.045 mg/mL, black) for 1 day (plain)
and 7 days (dashed). Results are expressed relative to the corresponding level of expression of each transcript in
the untreated sample; Figure S7, Quantitative real-time PCR data. Heat maps of gene transcript levels of (a) M1
markers and (b) M2 markers in inflamed samples (500 ng/mL of LPS) treated with culture media (IC,U, blue),
free dexamethasone (free Dx, 5.1 µM, red), Dx-loaded ketoprofen-bearing NPs (14Dx-KT NPs, 5.1 µM Dx, and
0.045 mg/mL NPs, white), and unloaded ketoprofen-bearing NPs (KT NPs, 0.045 mg/mL, black) for 1 day (plain)
or 7 days (dashed). Results are expressed relative to the corresponding level of expression of each transcript in
the non-inflammatory conditions (NIC) untreated sample; Table S1, RT-qPCR primer list; Table S2, Quantitative
real-time PCR data. Gene transcript levels of M1 markers under normal cellular conditions (NIC) and of M1 and
M2 markers under inflammatory conditions (IC,U), treated with free dexamethasone (free Dx, 5.1 µM), Dx-loaded
ketoprofen-bearing NPs (14Dx-KT NPs, 5.1 µM Dx, and 0.045 mg/mL NPs), and unloaded ketoprofen-bearing NPs
(KT NPs, 0.045 mg/mL) for 1 day or 7 days. Data are presented as mean log2 variation and standard deviation
compared to untreated cells in 2 independent experiments, each quantified in triplicate.
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